FOXO4-DRI for Health & Longevity

Created on 10/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

FOXO4-DRI is a laboratory-made peptide, sold online as a research chemical, designed to make worn-out cells that build up with age destroy themselves. In aged mice it restored kidney filtration and testosterone output; no person has taken it in a registered study. Concerns include loss of cells holding tissues together and worsened lung blood-vessel disease in mice, its action on the body's main defence against cancer, and possibly contaminated supply. (Full Review)

Protocol

No standard protocol and no practitioner source
No human protocol exists
Not approved anywhere; no clinic or prescriber supplies it
Published animal regimen
5 mg/kg every other day, three doses
Abdominal injection in naturally aged mice
Single versus split dosing
Repeated lower-concentration rounds
More potent than one higher exposure in culture; untested in humans
Time to effect
Organ-level readouts in mice
30 days
After a three-dose course
Senescent-cell death in culture
24–36 hours
After exposure
In humans
Unknown
No human outcome data exist

Benefits

Contraindications
  • Anyone with active or recently treated cancer, or known precancerous lesions
  • People with pulmonary hypertension (mean pulmonary arterial pressure above 20 mmHg) or chronic hypoxic lung disease
  • People with established liver fibrosis, cirrhosis or portal hypertension
  • People who are pregnant, trying to conceive, or breastfeeding
  • Anyone within weeks of surgery, major injury or an unhealed wound
Key Interactions
Theoretical (inferred from mechanism)
  • p53-activating chemotherapy (doxorubicin, cisplatin) and radiotherapy
  • Other senolytics (dasatinib, quercetin)
  • p53-pathway drugs (nutlin-3a and p53 inhibitors such as pifithrin-α)
  • Corticosteroids (prednisone) and interleukin-1 blockers (anakinra)
  • Over-the-counter anti-inflammatory medication (ibuprofen, naproxen)
  • Anti-inflammatory and senolytic supplements (fisetin, curcumin)
  • Lifestyle interventions with senolytic-like effects (vigorous exercise, prolonged fasting)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Endotoxin, impurity and dose error from unregulated supply
  • Speculative: Removal of senescent cells that hold tissue barriers together; worsening of pulmonary blood-vessel disease; interference with p53 tumour surveillance; immune reaction to the peptide and its carrier; off-target effects of the arginine-rich carrier

Monitoring

Marker Target Why
ALT and AST ALT 7–55 U/L; AST 8–48 U/L Safety check for liver injury
Serum creatinine with eGFR Creatinine 0.59–1.04 mg/dL (women), 0.74–1.35 mg/dL (men) Kidney filtration, the clearest change in treated mice
Blood urea nitrogen 6–24 mg/dL Primary kidney readout in the animal work
Platelet count 150–450 × 10⁹/L Safety check for platelet loss
High-sensitivity C-reactive protein No established target; track change from the individual's own baseline Inflammatory signalling from senescent cells
p16INK4a messenger RNA in CD3-positive blood T cells No established target; track change from the individual's own baseline Senescent-cell burden
Total testosterone (males) 264–916 ng/dL Testosterone recovery seen in aged male mice

Cadence: Baseline before any exposure, then at 2 weeks after a course, at 3 months, and every 3 to 6 months thereafter

Qualitative Assessment

  • Energy and fatigue
  • Exercise capacity and recovery time
  • Skin and hair condition
  • Sexual function and libido in males
  • Injection-site appearance and any fever or malaise in the 24 hours after exposure